Correction: Framework for developing cost-effectiveness analysis threshold: the case of Egypt.
Ahmad N Fasseeh, Nada Korra, Baher Elezbawy, Amal S Sedrak, Mary Gamal, Randa Eldessouki, Mariam Eldebeiky, Mohsen George, Ahmed Seyam, Asmaa Abourawash, Ahmed Y Khalifa, Mayada Shaheen, Sherif Abaza, Zoltán Kaló
Author Information
- Ahmad N Fasseeh: Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- Nada Korra: Syreon Middle East, Alexandria, Egypt. nada.korra@syreon.eu. ORCID
- Baher Elezbawy: Syreon Middle East, Alexandria, Egypt.
- Amal S Sedrak: Department of Public Health, Cairo University, Cairo, Egypt.
- Mary Gamal: Egyptian Authority for Unifed Procurement, Medical Supply and Technology Management, Cairo, Egypt.
- Randa Eldessouki: Department of Community Health, Fayoum University, Fayoum, Egypt.
- Mariam Eldebeiky: Egyptian Authority for Unifed Procurement, Medical Supply and Technology Management, Cairo, Egypt.
- Mohsen George: Universal Health Insurance Authority, Cairo, Egypt.
- Ahmed Seyam: Universal Health Insurance Authority, Cairo, Egypt.
- Asmaa Abourawash: Egyptian Drug Authority, Cairo, Egypt.
- Ahmed Y Khalifa: World Health Organization Representative Office, Cairo, Egypt.
- Mayada Shaheen: Roche, Cairo, Egypt.
- Sherif Abaza: Syreon Middle East, Alexandria, Egypt.
- Zoltán Kaló: Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
No abstract text available.
- J Egypt Public Health Assoc. 2024 Jun 3;99(1):12
[PMID: 38825614]
